PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes
about
Heated tobacco product regulation under US law and the FCTCModelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco productLight and mild redux: heated tobacco products' reduced exposure claims are likely to be misunderstood as reduced risk claimsHeated tobacco products: another tobacco industry global strategy to slow progress in tobacco control
P2860
PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2018
@uk
name
PMI's own in vivo clinical dat ...... t from conventional cigarettes
@en
PMI's own in vivo clinical dat ...... t from conventional cigarettes
@nl
type
label
PMI's own in vivo clinical dat ...... t from conventional cigarettes
@en
PMI's own in vivo clinical dat ...... t from conventional cigarettes
@nl
prefLabel
PMI's own in vivo clinical dat ...... t from conventional cigarettes
@en
PMI's own in vivo clinical dat ...... t from conventional cigarettes
@nl
P2860
P1433
P1476
PMI's own in vivo clinical dat ...... t from conventional cigarettes
@en
P2860
P304
P356
10.1136/TOBACCOCONTROL-2018-054413
P407
P433
P577
2018-11-01T00:00:00Z